Genoray
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Genoray makes X-ray imaging equipment used by hospitals and dental clinics to diagnose patients.
Its products serve two distinct customer groups: general medical facilities and dental practices. Listed on KOSDAQ, Korea's tech and small-cap exchange, the company operates both a medical division and a dental division simultaneously, a combination it describes as unique among domestic manufacturers.
Summary is AI-generated and may contain errors · figures from DART filings
Genoray in five facts
What does Genoray do?
Genoray makes X-ray imaging equipment used by hospitals and dental clinics to diagnose patients.
Where is Genoray listed and in which sector?
Genoray (Korean name: 제노레이) trades under KRX code 122310 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Genoray?
Its market capitalisation was US$34.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Genoray's latest annual revenue and operating profit?
For fiscal year 2025, Genoray reported revenue of US$81.5M, an operating loss of US$183.6K and net income of US$474.4K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 1.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision (quarterly dividend)
Genoray declared a cash dividend of US$0.04 per share, equal to about 1.5% of the recent share price.
Dividend · Oct 1 - DisclosureSep 28
- Report on large shareholdings (5% rule) (standard)Sep 16
- DisclosureSep 15
- Report on securities held by executives/major shareholdersSep 10
- Cash/in-kind dividend decision (quarterly dividend)
Genoray declared a cash dividend of US$0.03 per share, equal to about 1.5% of the recent share price.
Dividend · Jul 1 - Cash/in-kind dividend decision
Genoray declared a cash dividend of US$0.03 per share, equal to about 1.1% of the recent share price.
Dividend · Apr 1 - Operating results (consolidated) (preliminary) (fair disclosure)
Genoray filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$23.6M (+18.4% year on year), operating profit of US$1.05M (from a loss a year earlier) and net income of US$2.1M (from a loss a year earlier).
Earnings · Feb 12 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Genoray reported consolidated results for FY2025: revenue of US$74.8M (+1% year on year), an operating loss of US$73.9K (from a profit a year earlier) and net income of US$192K (from a loss a year earlier).
Earnings · Feb 12 - Treasury share disposal: results reportTreasury Shares · Jan 30
- Material event report (treasury share disposal)Treasury Shares · Jan 22
- Material event report (exchangeable bonds)Capital raise · Jan 22